Clinical Trial Update: Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics study of the investigational antibody Ianalumab in Chinese participants with autoimmune diseases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome
• Systemic Lupus Erythematosus

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sjogren Disease, Systemic Lupus Erythematosus | Phase 1 | Status: WITHDRAWN